| SEC Form 4 | | | | | | | | | | | | | |
|--|--|-------------|--|---|---|-----------------------------------|--|--|------------------------|--------------|---|--|--|
| FORI | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | OMB APPROVAL | | | |
| Check this box if r Section 16. Form obligations may ca Instruction 1(b). | STA | | oursua | F CHANGE ant to Section 16(a) action 30(h) of the I | ERSH | | OMB Num Estimated hours per i | average burde | 3235-0287 en 0.5 | | | | |
| 1. Name and Address of Reporting Person [*] <u>Mehrotra Parth</u> | | | | | uer Name and Tick ia Health Gro | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) President and COO | | | | | |
| (Last) PRIVIA HEALTI | (Last) (First) (Middle) PRIVIA HEALTH GROUP, INC. | | | | e of Earliest Trans 5/2023 | action (Month | /Day/Year) | | | | | | |
| 950 N. GLEBE RD., SUITE 700 | | | · | 4. If A | mendment, Date o | f Original File | d (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) ARLINGTON | VA | 22203 | | | | | | X | , | • | eporting Perso an One Repo | | |
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication X Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instr | | | | | | | | | | |
| | Ta | able I - No | on-Derivat | | | | posed of, or Benefi | | | | | | |
| | | | 2. Transactio Date (Month/Dav/) | | 2A. Deemed Execution Date, if any | 3. Transaction Code (Instr. | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) Benefici | | | Fo | Ownership orm: Direct) or Indirect | 7. Nature of Indirect Beneficial | |

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Code (Instr. | | 4. Securities A Disposed Of (| | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|---|-------------------------|---|----------------------------------|---------------|-------------------------------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (1150.4) |
| Common Stock, \$0.01 par value per share | 05/05/2023 | | М | | 100,000 | A | \$2 | 182,229 | D | |
| Common Stock, \$0.01 par value per share | 05/05/2023 | | S ⁽¹⁾ | | 108,577 | D | \$28.56 ⁽²⁾ | 73,652 | D | |
| Common Stock, \$0.01 par value per share | 05/05/2023 | | S ⁽¹⁾ | | 8,724 | D | \$29.04(3) | 64,928 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | tive Conversion Date ty or Exercise (Month/Day/Yea | | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr.) 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|------------|---|---|---|--|--------|--|--------------------|---|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Purchase) | \$2 | 05/05/2023 | | М | | | 75,496 | (4) | 12/04/2034 | Common Stock | 75,496 | \$0 | 113,066 | D | |
| Stock Option (Right to Purchase) | \$2 | 05/05/2023 | | М | | | 24,504 | (4) | 08/27/2033 | Common Stock | 24,504 | \$0 | 249,055 | D | |

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2022.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$28.00 to \$28.99 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. The price reported in Column 4 is a weighted average price. The shared were sold in multiple transactions at prices ranging from \$29.00 to \$29.12 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

4. All stock options are fully vested and exercisable.

Remarks:

<u>/s/ Thomas Bartrum, as</u> <u>attorney-in-fact</u>

05/09/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.